532 related articles for article (PubMed ID: 22197931)
21. Dynamic Evolution of Clonal Composition and Neoantigen Landscape in Recurrent Metastatic Melanoma with a Rare Combination of Driver Mutations.
Davidson G; Coassolo S; Kieny A; Ennen M; Pencreach E; Malouf GG; Lipsker D; Davidson I
J Invest Dermatol; 2019 Aug; 139(8):1769-1778.e2. PubMed ID: 30776432
[TBL] [Abstract][Full Text] [Related]
22. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
23. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
[TBL] [Abstract][Full Text] [Related]
24. 17-Aminogeldanamycin selectively diminishes IRE1α-XBP1s pathway activity and cooperatively induces apoptosis with MEK1/2 and BRAF
Mielczarek-Lewandowska A; Sztiller-Sikorska M; Osrodek M; Czyz M; Hartman ML
Apoptosis; 2019 Aug; 24(7-8):596-611. PubMed ID: 30989459
[TBL] [Abstract][Full Text] [Related]
25. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
Falchook GS; Lewis KD; Infante JR; Gordon MS; Vogelzang NJ; DeMarini DJ; Sun P; Moy C; Szabo SA; Roadcap LT; Peddareddigari VG; Lebowitz PF; Le NT; Burris HA; Messersmith WA; O'Dwyer PJ; Kim KB; Flaherty K; Bendell JC; Gonzalez R; Kurzrock R; Fecher LA
Lancet Oncol; 2012 Aug; 13(8):782-9. PubMed ID: 22805292
[TBL] [Abstract][Full Text] [Related]
26. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
27. Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival.
Cartlidge RA; Thomas GR; Cagnol S; Jong KA; Molton SA; Finch AJ; McMahon M
Pigment Cell Melanoma Res; 2008 Oct; 21(5):534-44. PubMed ID: 18715233
[TBL] [Abstract][Full Text] [Related]
28. Mutation and phenotypic spectrum in patients with cardio-facio-cutaneous and Costello syndrome.
Schulz AL; Albrecht B; Arici C; van der Burgt I; Buske A; Gillessen-Kaesbach G; Heller R; Horn D; Hübner CA; Korenke GC; König R; Kress W; Krüger G; Meinecke P; Mücke J; Plecko B; Rossier E; Schinzel A; Schulze A; Seemanova E; Seidel H; Spranger S; Tuysuz B; Uhrig S; Wieczorek D; Kutsche K; Zenker M
Clin Genet; 2008 Jan; 73(1):62-70. PubMed ID: 18042262
[TBL] [Abstract][Full Text] [Related]
29. Frequent somatic mutations in MAP3K5 and MAP3K9 in metastatic melanoma identified by exome sequencing.
Stark MS; Woods SL; Gartside MG; Bonazzi VF; Dutton-Regester K; Aoude LG; Chow D; Sereduk C; Niemi NM; Tang N; Ellis JJ; Reid J; Zismann V; Tyagi S; Muzny D; Newsham I; Wu Y; Palmer JM; Pollak T; Youngkin D; Brooks BR; Lanagan C; Schmidt CW; Kobe B; MacKeigan JP; Yin H; Brown KM; Gibbs R; Trent J; Hayward NK
Nat Genet; 2011 Dec; 44(2):165-9. PubMed ID: 22197930
[TBL] [Abstract][Full Text] [Related]
30. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
[TBL] [Abstract][Full Text] [Related]
31. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.
Tidyman WE; Rauen KA
Methods Mol Biol; 2010; 661():433-47. PubMed ID: 20812000
[TBL] [Abstract][Full Text] [Related]
32. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
[TBL] [Abstract][Full Text] [Related]
33. Germline mutations of MEK in cardio-facio-cutaneous syndrome are sensitive to MEK and RAF inhibition: implications for therapeutic options.
Senawong T; Phuchareon J; Ohara O; McCormick F; Rauen KA; Tetsu O
Hum Mol Genet; 2008 Feb; 17(3):419-30. PubMed ID: 17981815
[TBL] [Abstract][Full Text] [Related]
34. The MEK1/2 inhibitor AS703026 circumvents resistance to the BRAF inhibitor PLX4032 in human malignant melanoma cells.
Park SJ; Hong SW; Moon JH; Jin DH; Kim JS; Lee CK; Kim KP; Hong YS; Choi EK; Lee JS; Lee JL; Kim TW
Am J Med Sci; 2013 Dec; 346(6):494-8. PubMed ID: 24051957
[TBL] [Abstract][Full Text] [Related]
35. [New treatment options for metastatic melanoma].
Tietze JK; Berking C
Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194
[No Abstract] [Full Text] [Related]
36. BRAF somatic mutations in malignant melanoma and melanocytic naevi.
Thomas NE
Melanoma Res; 2006 Apr; 16(2):97-103. PubMed ID: 16567964
[TBL] [Abstract][Full Text] [Related]
37. ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma.
Hutchinson KE; Johnson DB; Johnson AS; Sanchez V; Kuba M; Lu P; Chen X; Kelley MC; Wang Q; Zhao Z; Kris M; Berger MF; Sosman JA; Pao W
Oncotarget; 2015 Sep; 6(26):22348-60. PubMed ID: 26084293
[TBL] [Abstract][Full Text] [Related]
38. MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas.
Murugan AK; Dong J; Xie J; Xing M
Cell Cycle; 2009 Jul; 8(13):2122-4. PubMed ID: 19411838
[TBL] [Abstract][Full Text] [Related]
39. Impact of Sun Exposure and Tanning Patterns on Next-Generation Sequencing Mutations in Melanoma.
Loo K; Soliman I; Renzetti M; Li T; Wu H; Reddy S; Olszanski AJ; Farma JM
J Surg Res; 2020 Oct; 254():147-153. PubMed ID: 32445930
[TBL] [Abstract][Full Text] [Related]
40. Activation of the mitogen-activated protein kinase pathway in malignant melanoma can occur independently of the BRAF T1799A mutation.
Yazdi AS; Ghoreschi K; Sander CA; Röcken M
Eur J Dermatol; 2010; 20(5):575-9. PubMed ID: 20605766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
